Table 4. Comparisons of differential values (DV, post-administration minus pre-administration) in type 2 diabetes patients with different PPAR-γ2 rs1801282 and PTPRD rs17584499 polymorphisms after pioglitazone treatment (n=67).

Parameters	PPAR-γ2 rs1801282			PTPRD rs17584499
	CC	CG	P	CC	CT+TT	P
No (male/female)	60 (35/25)	7 (4/3)	0.952Δ	45 (24/21)	22 (15/7)	0.247Δ
DV FPG (mmol/L)	-1.23±1.24	-2.24±0.82	0.015†,b	-1.36±1.17	-1.29±1.39	0.830#
DV PPG (mmol/L)	-2.56±3.55	-0.45±2.78	0.260†	-3.18±3.37	-0.63±3.26	0.005%#,c
DV HbA1c (%)	-0.75±1.24	-1.39±0.93	0.132†	-0.92±1.31	-0.61±1.01	0.303†
DV TC (mmol/L)	-0.36±0.79	-0.10±1.06	0.539†	-0.40±0.85	-0.17±0.75	0.130†
DV TG (mmol/L)	-0.27±0.82	-0.89±0.48	0.010†,b	-0.35±0.82	-0.30±0.79	0.530†
DV HDL-c (mmol/L)	-0.08±0.36	-0.08±0.62	0.830†	-0.09±0.40	-0.00±0.38	0.857†
DV LDL-c (mmol/L)	-0.34±0.80	-0.16±0.99	0.580#	-0.39±0.83	-0.18±0.77	0.400†

DV, differential value (3 months post-administration minus 0 month pre-administration); FPG, fasting plasma glucose; PPG, postprandial plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.

^ΔP values are determined by Pearson χ² test.

^#P values are assessed by two-sample t-test.

^†P values are determined by Mann-Whitney test.

^bP<0.05,

^cP<0.01.